Astronomers make groundbreaking discovery about largest comet ever observed flying through deep space
A groundbreaking discovery was recently made about the largest comet ever observed hurtling toward the sun from the Oort Cloud in the outer reaches of our solar system.
Astronomers recently got a close-up look at the comet, known as C/2014 UN271, flying through deep space with the powerful Atacama Large Millimeter/submillimeter Array (ALMA) radio telescope in Chile.
The icy giant is 85 miles across and is more than 10 times the size of any known comet, according to the National Radio Astronomy Observatory (NRAO).
The NRAO reported that astronomers found that new observations from the comet showed jets of carbon monoxide gas erupting out from the comet's solid icy core.
Using the ALMA, the researchers found the comet in deep space near Neptune or about 17 times the distance between the Sun and Earth, according to a release from NRAO.
Using the ALMA telescope's high sensitivity and resolution, the researchers were able to focus on the carbon monoxide and heat being emitted from the comet.
Nathan Roth of American University and NASA Goddard Space Flight Center, the lead author of the study, which was published in the Astrophysical Journal Letters, discussed how this gives researchers insight into the workings of this frozen rock hurtling through space.
4 Astronomers discovered jets of carbon monoxide gas erupting out from the comet's solid icy core.
NRAO/Melissa Weiss
4 The comet was spotted in deep space near Neptune.
NASA Goddard
'These measurements give us a look at how this enormous, icy world works,' Roth said. 'We're seeing explosive outgassing patterns that raise new questions about how this comet will evolve as it continues its journey toward the inner solar system.'
Using previous ALMA observations and these newest findings, researchers were able to measure the comet.
They measured the thermal signal to find the comet's size and amount of dust surrounding its core.
4 Scientists hope the new data will give them a better understanding of the makeup of the solar system.
AP
4 Researchers used the ALMA telescope to track the carbon monoxide and heat being emitted from the comet.
Diogo Josí© – stock.adobe.com
Researchers believe that as C/2014 UN271 gets closer to the sun, they will see more frozen gas begin to vaporize off the titan of a comet.
This could possibly give researchers more information about the primitive makeup of this icy giant.
The researchers also hope that this will give a better understanding of the makeup of the solar system.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
DOYLESTOWN, Pa., June 27, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced that its drug candidate, ENT-03, showed significant benefit in metabolic dysfunction in addition to sustaining weight loss, improvement in blood glucose, and insulin sensitivity in comparison to semaglutide in an animal model for obesity. "Metabolics Pharma spun off from its parent company, Enterin, in late 2024 so that the company could focus its efforts on and enhance the value of its lead asset, ENT-03, for the treatment of obesity and certain comorbidities," said Richard Larson, M.D., Ph.D., Chief Executive Officer, Chief Medical Officer and Board Chairman of Metabolics Pharma. "These preclinical data highlight both the promise and potential value of ENT-03 in the treatment of metabolic disease. The research shows that ENT-03 clearly improves insulin sensitivity and sustained weight reduction that persists following cessation of treatment. This research is the foundation for our Phase 1 clinical trials in healthy obese and diabetic obese subjects." ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism. In obese, diabetic mice, ENT-03 rapidly lowers blood glucose, reduces food intake and adiposity, eliminates liver fat, and improves liver function. This study compared ENT-03 to semaglutide, a combination of the two compounds, and vehicle in Diet Induced Obesity (DIO) mice. While the vehicle-treated mice gained weight through the duration of the study, mice treated with ENT-03, Semaglutide, or a combination of the two drugs all lost weight and reduced insulin and glucose levels. ENT-03 showed a greater reduction in weight than Semaglutide over the 10-week treatment period. Additive weigh loss was seen when the drugs were used in combination. After cessation of therapy, weight loss and reduction in glucose and insulin were sustained for an additional two months in the ENT-03 treated mice but not Semaglutide treated mice. In addition, ENT-03 showed substantially greater preservation of lean mass in comparison to other treatment groups. "GLP-1 agonists have revolutionized the treatment of obesity and type 2 diabetes," said Richard Larson, MD, PhD. "However, their impressive efficacy comes at the price of tolerability challenges, the loss of lean body mass, and the need to remain on treatment to sustain weight loss. ENT-03 represents a novel drug candidate that could be an alternative treatment to GLP-1 agonists or used in combination with them. We believe that ENT-03 could have a substantial impact on the obesity drug market since it has potential benefits beyond weight loss." Metabolics Pharma has completed a Phase 1a, first in human, randomized, double-blind, single ascending dose study of ENT-03. Results of the Phase 1a trial were presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. A Phase 1b clinical trial is planned to initiate in the second half of 2025. About Metabolics Pharma Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity and type 2 diabetes. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit View source version on Contacts Richard Larson, M.D., Executive Officer, Chief Medical Officer, and Chairman of the Board John DessoukiChief Financial Sign in to access your portfolio
Business Wire
15 hours ago
- Business Wire
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
DOYLESTOWN, Pa.--(BUSINESS WIRE)--Metabolics Pharma ('Metabolics'), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced that its drug candidate, ENT-03, showed significant benefit in metabolic dysfunction in addition to sustaining weight loss, improvement in blood glucose, and insulin sensitivity in comparison to semaglutide in an animal model for obesity. 'Metabolics Pharma spun off from its parent company, Enterin, in late 2024 so that the company could focus its efforts on and enhance the value of its lead asset, ENT-03, for the treatment of obesity and certain comorbidities,' said Richard Larson, M.D., Ph.D., Chief Executive Officer, Chief Medical Officer and Board Chairman of Metabolics Pharma. 'These preclinical data highlight both the promise and potential value of ENT-03 in the treatment of metabolic disease. The research shows that ENT-03 clearly improves insulin sensitivity and sustained weight reduction that persists following cessation of treatment. This research is the foundation for our Phase 1 clinical trials in healthy obese and diabetic obese subjects.' ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism. In obese, diabetic mice, ENT-03 rapidly lowers blood glucose, reduces food intake and adiposity, eliminates liver fat, and improves liver function. This study compared ENT-03 to semaglutide, a combination of the two compounds, and vehicle in Diet Induced Obesity (DIO) mice. While the vehicle-treated mice gained weight through the duration of the study, mice treated with ENT-03, Semaglutide, or a combination of the two drugs all lost weight and reduced insulin and glucose levels. ENT-03 showed a greater reduction in weight than Semaglutide over the 10-week treatment period. Additive weigh loss was seen when the drugs were used in combination. After cessation of therapy, weight loss and reduction in glucose and insulin were sustained for an additional two months in the ENT-03 treated mice but not Semaglutide treated mice. In addition, ENT-03 showed substantially greater preservation of lean mass in comparison to other treatment groups. 'GLP-1 agonists have revolutionized the treatment of obesity and type 2 diabetes,' said Richard Larson, MD, PhD. 'However, their impressive efficacy comes at the price of tolerability challenges, the loss of lean body mass, and the need to remain on treatment to sustain weight loss. ENT-03 represents a novel drug candidate that could be an alternative treatment to GLP-1 agonists or used in combination with them. We believe that ENT-03 could have a substantial impact on the obesity drug market since it has potential benefits beyond weight loss.' Metabolics Pharma has completed a Phase 1a, first in human, randomized, double-blind, single ascending dose study of ENT-03. Results of the Phase 1a trial were presented at the American Diabetes Association 85 th Scientific Sessions on June 22, 2025. A Phase 1b clinical trial is planned to initiate in the second half of 2025. About Metabolics Pharma Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity and type 2 diabetes. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit
Yahoo
15 hours ago
- Yahoo
Astronomers discover baby planets taking their 1st steps in nearby stellar nursery (images)
When you buy through links on our articles, Future and its syndication partners may earn a commission. Astronomers may have caught the first stages of planets being born around infant stars. The discovery came about when a team of scientists studied 78 planet-forming, flattened clouds of gas and dust, or "protoplanetary disks," in the Ophiuchus star-forming region. This stellar nursery, also known as the Rho Ophiuchi cloud complex, is located around 460 light-years from Earth, making it the closest star-forming region to our solar system. The team discovered previously unseen rings, spirals and other substructures in the swirling, plate-like planet-forming clouds around a number of stars just a few hundred thousand years old. If that seems ancient, consider this: Our middle-aged star, the sun, is 4.6 billion years old. The team's findings suggest stars and planets evolve together in environments that are rich in gas and dust. Stars are born when overly dense regions in vast clouds of gas and dust called molecular clouds collapse under their own gravity. This collapse creates a protostar wrapped in a pre-natal envelope of material from which it continues to gather mass. This matter-harvesting continues until the star is sufficiently massive enough to trigger the fusion of hydrogen to helium at the heart of the star, the nuclear process that defines what a fully grown or main-sequence star end result is a young star surrounded by a flattened disk of gas and dust within which planets can begin to form. When planets begin to take shape in these disks, their gravitational influence can gather or eject materials. That process gives rise to substructures in the protoplanetary disk. However, the big question is: At what point in the evolution of planetary systems do these substructures begin to appear? That's a question astronomers have been attempting to answer using the Atacama Large Millimeter/submillimeter Array (ALMA), an array of 66 antennas in northern Chile that work together to act as form a single telescope. In particular, two large programs conducted by ALMA, DSHARP and eDisk, have discovered intricate details of structures in protoplanetary disks. DSHARP found that such structures are common in the disks that surround 20 young stars under 1 million years of age. Meanwhile, eDisk studied younger protostars that are just between 10,000 and 100,000 years old and thus still in their matter-harvesting stage. This revealed that structures present around 1 million-year-old stars are absent around stars 10 and 100 times younger. That implies the characteristics of a protoplanetary disk are dependent on the age of its central star. The new study's team looked at stars with ages between those studied in the DSHARP and eDisk programs, turning to super-resolution imaging provided by public software called "Python module for Radio Interferometry Imaging with Sparse Modeling," or (PRIISM), and applied this to ALMA archival data. This allowed the researchers to obtain a resolution three times greater than what's provided by standard procedures for half of the imaged protoplanetary disks. The team's results were further bolstered by the fact their Ophiuchus sample was four times larger than what was used in the DSHARP and eDisk programs. The investigation revealed 27 of the 78 examined disks had ring or spiral structures, 15 of which had never been seen before. This revealed substructures form in disks that have widths 30 times the distance between Earth and the sun (30 astronomical units). This, in turn, implies that substructures form much earlier than previously thought — while such disks are still abundant with gas and dust. In other words, infant stars and planets seem to evolve together — at least, in the Ophiuchus stellar nursery. Related Stories: —The deadly atmosphere on Venus could help us find habitable worlds. Here's how. — Could nearby stars have habitable exoplanets? NASA's Chandra X-ray Observatory hopes to find out — Astronomers discover origins of mysterious double hot Jupiter exoplanets: 'It is a dance of sorts' "These findings, bridging the gap between the eDisk and DSHARP projects, were enabled by the innovative imaging that allows for both achieving high resolution and a large number of samples," Ayumu Shoshi, team leader and a researcher at Kyushu University, said in a statement. "While these findings only pertain to the disks in Ophiuchus, future studies of other star-forming regions will reveal whether this tendency is universal." The team's research was published in The Publications of the Astronomical Society of Japan
